Walking Fish Therapeutics Launches With $50 Million In Series A Financing To Accelerate Development Of B Cell Therapies For Multiple Diseases
Amount Raised
$50 Million
Round Type
Series A
San FranciscoBiotechnologyHealth CareScience And EngineeringDescription
Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
Who to call at Walking Fish Therapeutics, and when
A new round usually means Walking Fish Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Walking Fish Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Walking Fish Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Walking Fish Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Walking Fish Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansWalking Fish Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.